Catalyst Brief

← Calendar

Readoutin 14d

Jiangsu HengRui Medicine Co., Ltd. — Fuzuloparib , Abiraterone acetate and Prednisone

Phase 3 primary completion: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer.

Date
Dec 2026
Type
Readout
Indication
Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Jiangsu HengRui Medicine Co., Ltd.

  1. Dec2026
  2. Dec2026